Detailed Narrative
Robust Q2 & H1 FY26 Financial Performance
Innova Captab demonstrated strong financial performance in Q2 and H1 FY26. Consolidated revenue for Q2 FY26 reached INR380.4 crores, marking a 19.5% year-on-year growth. For the first half of FY26, the top line stood at INR731.9 crores, also growing by 19.5%. EBITDA for Q2 FY26 was INR56.1 crores, an 8% increase YoY, while H1 FY26 EBITDA grew 17% to INR112.6 crores. The company maintained healthy EBITDA margins of 14.7% in Q2 and 15.4% in H1, with PAT at INR29.7 crores and INR60.7 crores respectively.
Segmental Growth Driven by CDMO and Branded Generics
Both core business segments contributed significantly to the overall growth. The CDMO (Contract Development and Manufacturing Organization) operations, serving over 300 clients globally, reported a 15% YoY growth in Q2 FY26, achieving INR265.7 crores in revenue. For H1 FY26, CDMO revenue totaled INR515.2 crores. The Branded Generics business exhibited even stronger growth, with a 31% YoY increase to INR114.6 crores in Q2 FY26 and a 43% YoY growth to INR216.7 crores in H1 FY26, driven by product basket expansion and enhanced marketing efforts.
Jammu Facility: A Key Growth Engine and Capacity Expansion
The newly commissioned Jammu facility is a strategic asset for future growth. Innova Captab has invested approximately INR480 crores in this facility. Management projects that at an optimum capacity utilization of 65-70%, the Jammu plant can achieve peak revenue of north of INR1,400 crores. The ramp-up plan for the facility is set for 3-4 years, aiming to reach over INR1,000 crores in revenue. For H2 FY26, the company expects Jammu sales to reach INR270-280 crores, a revision from the earlier INR400 crores target.
Impact of GST Rate Reduction and Mitigation Strategy
The central government's reduction of the GST rate on pharmaceutical formulations from 12% to 5% directly impacts the GST incentive received from the Jammu facility. While the overall quantum of the INR75-80 crores maximum incentive remains the same, the company will now need to achieve annual sales of approximately INR1,400 crores (up from INR650 crores) to realize the full benefit. Management indicated that the 7% reduction would not directly hit the P&L, as pricing strategies with B2B customers would be redefined to account for the reduced advantage.
Regulatory Compliance and Market Dynamics
Innova Captab's manufacturing capabilities were strengthened by successful inspections from the UK-MHRA for its Cephalosporin plant in Baddi and the State Service of Ukraine on Medicine and Drug Control (SMDC) for its Jammu facility. Management acknowledged the increasing stringency of regulatory agencies globally, including CDSCO, emphasizing the company's proactive approach to compliance. Despite a challenging backdrop of declining API prices impacting the CDMO business, early signs of price stabilization are now being observed, which is a positive indicator for future quarters.
Outlook and Margin Sustainability
The company remains optimistic about sustaining its growth momentum, supported by a strong order book. Management reiterated its commitment to maintaining a 20% plus growth trajectory, aiming to double its top line, EBITDA, and PAT within the next three years from its post-IPO base of INR1,000-1,200 crores. EBITDA margins are expected to remain stable within the 13-17% range, with a long-term target of 15% sustainability, even considering the GST changes, as unit efficiencies improve.